Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxwell D Cummings

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
A novel series of potent and selective small molecule inhibitors of the complement component C1sNalin L Subasinghe, Farah Ali, Carl R Illig, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2006
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug designDaniel J Parks, Louis V LaFrance, Raul R Calvo, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2019
3-Substituted Quinolines as RORγt Inverse AgonistsVirginia M Tanis, Hariharan Venkatesan, Maxwell D Cummings, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2012
TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverageBenoit Devogelaere, Jan Martin Berke, Leen Vijgen, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
Journal of Medicinal Chemistry|October 28, 2005
Azepanone-based inhibitors of human cathepsin LRobert W Marquis, Ian James, Jin Zeng, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymeraseMaxwell D Cummings, Tse-I Lin, Lili Hu, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2018
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapyTianbao Lu, Carsten Schubert, Maxwell D Cummings, et al.
Bioorganic & Medicinal Chemistry Letters|March 21, 2017
Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγtDavid A Kummer, Maxwell D Cummings, Marta Abad, et al.
Journal of Medicinal Chemistry|April 16, 2025
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of PsoriasisOlaf Kinzel, Steven D Goldberg, Maxwell D Cummings, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
A novel series of potent and selective small molecule inhibitors of the complement component C1sNalin L Subasinghe, Farah Ali, Carl R Illig, et al.
Bioorganic & Medicinal Chemistry Letters|April 8, 2006
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug designDaniel J Parks, Louis V LaFrance, Raul R Calvo, et al.
Bioorganic & Medicinal Chemistry Letters|April 24, 2019
3-Substituted Quinolines as RORγt Inverse AgonistsVirginia M Tanis, Hariharan Venkatesan, Maxwell D Cummings, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2012
TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverageBenoit Devogelaere, Jan Martin Berke, Leen Vijgen, et al.
Antimicrobial Agents and Chemotherapy|February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
Journal of Medicinal Chemistry|October 28, 2005
Azepanone-based inhibitors of human cathepsin LRobert W Marquis, Ian James, Jin Zeng, et al.
Journal of Medicinal Chemistry|October 23, 2013
Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymeraseMaxwell D Cummings, Tse-I Lin, Lili Hu, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2018
Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapyTianbao Lu, Carsten Schubert, Maxwell D Cummings, et al.
Bioorganic & Medicinal Chemistry Letters|March 21, 2017
Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγtDavid A Kummer, Maxwell D Cummings, Marta Abad, et al.
Journal of Medicinal Chemistry|April 16, 2025
Identification of JNJ-61803534, a RORγt Inverse Agonist for the Treatment of PsoriasisOlaf Kinzel, Steven D Goldberg, Maxwell D Cummings, et al.
Pageof 6